Shots:

• Novartis plans spin-off of its eye care business with an expected 100% spin-off on Apr 9- 2019 and has secured debt financing of $3.5B through banks
• Novartis stockholder to receive Alcon share for every 5 Novartis shares/ADRs prior to the closing of trade on Apr 8- 2019 and will be listed on SIX and the NYSE under the ticker ALC
• In 2011- Novartis acquired Alcon stake from Nestle for $39B to expand its ophthalmology portfolio. Novartis initially acquired only 25% of Alcon’s share for $11B and later acquired remaining shares for $28B

Click here to read full press release/ article | Ref: Exscientia | Image: Endpoints News